14-day Premium Trial Subscription Try For FreeTry Free
$8.76
+0.180 (+2.10%)
At Close: May 01, 2024
Forecast Earnings Fundamentals Insider Trading Signals Historical Prices Predictions News Profile

Range Low Price High Price Comment
30 days $7.97 $10.47 Wednesday, 1st May 2024 ZYME stock ended at $8.76. This is 2.10% more than the trading day before Tuesday, 30th Apr 2024. During the day the stock fluctuated 5.26% from a day low at $8.55 to a day high of $9.00.
90 days $7.97 $13.14
52 weeks $6.02 $13.14

Historical Zymeworks Inc prices

Date Open High Low Close Volume
Mar 26, 2024 $10.48 $10.61 $10.44 $10.47 337 767
Mar 25, 2024 $10.51 $10.55 $10.29 $10.40 257 879
Mar 22, 2024 $10.67 $10.67 $10.48 $10.52 243 730
Mar 21, 2024 $10.83 $10.98 $10.59 $10.65 282 634
Mar 20, 2024 $10.56 $10.88 $10.34 $10.75 398 758
Mar 19, 2024 $10.61 $10.77 $10.51 $10.53 984 343
Mar 18, 2024 $10.80 $10.90 $10.45 $10.71 383 880
Mar 15, 2024 $10.73 $10.90 $10.62 $10.81 557 520
Mar 14, 2024 $10.73 $11.03 $10.64 $10.77 432 367
Mar 13, 2024 $10.81 $10.99 $10.69 $10.75 451 218
Mar 12, 2024 $11.15 $11.38 $10.81 $10.81 490 830
Mar 11, 2024 $11.47 $11.59 $11.03 $11.05 405 699
Mar 08, 2024 $11.22 $11.85 $11.05 $11.44 626 332
Mar 07, 2024 $11.38 $12.48 $11.25 $11.44 1 507 160
Mar 06, 2024 $12.10 $12.48 $12.08 $12.23 472 064
Mar 05, 2024 $12.36 $12.55 $11.85 $11.98 397 750
Mar 04, 2024 $12.51 $12.67 $12.34 $12.51 369 242
Mar 01, 2024 $12.05 $12.55 $11.92 $12.51 384 958
Feb 29, 2024 $12.28 $12.44 $11.96 $12.01 552 329
Feb 28, 2024 $12.80 $12.90 $12.05 $12.06 362 793
Feb 27, 2024 $12.52 $13.14 $12.43 $12.90 534 430
Feb 26, 2024 $11.93 $12.42 $11.89 $12.37 218 605
Feb 23, 2024 $11.88 $12.06 $11.73 $11.94 390 345
Feb 22, 2024 $11.93 $12.23 $11.68 $11.93 279 266
Feb 21, 2024 $12.01 $12.24 $11.62 $11.74 293 073
Click to get the best stock tips daily for free!

About Zymeworks Inc

Zymeworks Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and colorectal cancer; and ZW49, a biparatopic anti-human epidermal growth factor receptor 2 ... ZYME Profile

Golden Star

Ticker Date Change Price
HRB Apr 29 1.00% $47.23
LYG Apr 29 0.391% $2.56
ORA Apr 29 1.95% $64.48
ETSY Apr 26 3.43% $67.43
DHT Apr 24 0.98% $11.28
LPLA Apr 19 1.10% $262.59
MLI Apr 19 7.29% $52.28
PFLT Apr 18 1.33% $11.25
DOOR Apr 18 0.94% $131.39
OCSL Apr 17 0.360% $19.43
Unlock

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT